EMEA-002819-PIP01-20

Table of contents

Key facts

Active substance
Magrolimab
Therapeutic area
Oncology
Decision number
P/0531/2021
PIP number
EMEA-002819-PIP01-20
Pharmaceutical form(s)
  • Concentrate for solution for infusion
  • Age-appropriate dosage form for parenteral use
Condition(s) / indication(s)
  • Treatment of acute myeloid leukaemia
  • Treatment of myelodysplastic syndromes, including juvenile myelomonocytic leukemia
Route(s) of administration
Intravenous use
Contact for public enquiries
Gilead Sciences International Ltd.

Tel. +44 (0)1223 897 300
E-mail: regulatory.pip@gilead.com
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating